Novel intriguing strategies attenuating to sarcopenia

Area of Science:

• Gerontology and Muscle Physiology
• Molecular Biology and Therapeutics

Background:

• Sarcopenia, characterized by age-related skeletal muscle mass and quality decline, leads to reduced mobility, strength, and increased fall risk.
• Molecular mediators of muscle fiber size, mitochondrial homeostasis, and apoptosis are key targets for sarcopenia drug discovery.
• Current strategies include resistance training and amino acid supplements to combat muscle wasting and weakness.

Purpose of the Study:

• To review recent therapeutic strategies for counteracting sarcopenia.
• To evaluate the potential of novel agents and molecular pathways in mitigating age-related muscle loss.

Main Methods:

• Review of recent scientific literature on sarcopenia therapeutics.
• Analysis of therapeutic strategies including myostatin inhibition, proteasome inhibition, and supplementation with eicosapentaenoic acid (EPA) and ursolic acid.
• Exploration of the role of peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) activation.

Main Results:

• Myostatin inhibitors show promise, with advanced trials in muscular dystrophy.
• Eicosapentaenoic acid (EPA) and ursolic acid demonstrate effectiveness in attenuating muscle degeneration symptoms.
• Activation of PGC-1α in skeletal muscle presents an intriguing therapeutic avenue for sarcopenia.
• Proteasome inhibitors and antioxidants may not positively influence age-related muscle loss.

Conclusions:

• Emerging therapies, including myostatin inhibitors and specific supplements like EPA, offer potential for treating sarcopenia.
• Targeting molecular pathways like PGC-1α activation presents a promising strategy for combating age-related muscle decline.
• Further research is needed to confirm the efficacy of these interventions specifically for sarcopenia.